MedTrace Logo

Open-Trial of EPI-743 for Adults With Tourette Syndrome

NCT01719523 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-03-05

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of EPI-743 on tic severity in adults with Tourette syndrome.

Conditions

  • Tourette Syndrome

Interventions

DRUG

EPI-743

Sponsors & Collaborators

  • Rembrandt Foundation

    collaborator UNKNOWN

  • Edison Pharmaceuticals Inc

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • Michael H Bloch, MD, MS · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719523 on ClinicalTrials.gov